TY - JOUR A1 - Scherer, Ulrich W. A1 - Hör, G. A1 - Hertel, A. T1 - Positronen-Emissions-Tomographie des Herzens / G. Hör, A. Hertel, U. W. Scherer JF - Herzerkrankungen und Interventionsmöglichkeiten / F. Unger [Hrsg.] Y1 - 1998 SN - 3-540-62916-5 SP - 236 EP - 263 PB - Springer CY - Berlin ER - TY - JOUR A1 - Scherer, Ulrich W. A1 - Hör, G. T1 - Kompartimentmodelle zur Quantifizierung des myokardialen Stoffwechsels mit PET / U. W. Scherer, G. Hör JF - Kardiologische Nuklearmedizin / G. Hör [Hrsg.] Y1 - 1997 SN - 3-609-62970-3 SP - 179 EP - 189 PB - ecomed CY - Landsberg ER - TY - JOUR A1 - Scherer, Ulrich W. A1 - Hör, G. T1 - Artifacts and Pitfalls in FDG-PET Whole-Body Scans / U.W. Scherer, G. Hör JF - Radionuclides for Mammary Gland - Current Status and Future Aspects / G. S. Limouris [Hrsg.] Y1 - 1997 SN - 960-85227-6-5 SP - 37 EP - 42 PB - Mediterra Publishers CY - Athen ER - TY - JOUR A1 - Scherer, Ulrich W. A1 - Heßberger, F. P. A1 - Gäggeler, H. W. A1 - Armbruster, P. T1 - The New Nuclide 225U / F.P. Heßberger, H. Gäggeler, P. Armbruster, W. Brüchle, H. Folger, S. Hofmann, D. Jost, J.V. Kratz, M.E. Leino, G. Münzenberg, V. Ninov, M. Schädel, U.W. Scherer, K. Sümmerer, A. Türler, D. Ackerman JF - Zeitschrift für Physik A Hadrons and Nuclei. 333 (1989), H. 1 Y1 - 1989 SN - 0939-7922 SP - 111 EP - 112 ER - TY - JOUR A1 - Scherer, Ulrich W. A1 - Gäggeler, H. W. A1 - Jost, D. T. A1 - Türler, A. T1 - Cold Fusion Reactions with 48Ca / H.W. Gäggeler, D.T. Jost, A. Türler, P. Armbruster, W. Brüchle, H. Folger, F.P. Heßberger, S. Hofmann, G. Münzenberg, V. Ninov, W. Reisdorf, M. Schädel, K. Sümmerer, J.V. Kratz, U. Scherer, M.E. Leino JF - Nuclear Physics A . 502 (1989), H. 1 Y1 - 1989 SN - 0375-9474 SP - 561 EP - 570 ER - TY - JOUR A1 - Scherer, Ulrich W. A1 - Gäggeler, H. W. A1 - Jost, D. T. A1 - Kovacs, J. T1 - Gas Phase Chromatography Experiments with Bromides of Tantalum and Element 105 / H.W. Gäggeler, D.T. Jost, J. Kovacs, U.W. Scherer, A. Weber, D. Vermeulen, A. Türler, K.E. Gregorich, R.A. Henderson, K.R. Czerwinski, B. Kadkhodayan, D.M. Lee, M. Nurmia, D. JF - Radiochimica Acta. 57 (1992) Y1 - 1992 SN - 0033-8230 SP - 93 EP - 100 ER - TY - JOUR A1 - Scherer, Ulrich W. A1 - Gober, M. K. A1 - Kratz, J. V. A1 - Zimmermann, H. P. T1 - Chemical Properties of Element 105 in Aqueous Solution: Extractions into Diisobutylcarbinol / M.K. Gober, J.V. Kratz, H.P. Zimmermann, M. Schädel, W. Brüchle, E. Schimpf, K.E. Gregorich, A. Türler, N.J. Hannink, K.R. Czerwinski, B. Kadkhodayan, D.M. Lee, JF - Radiochimica Acta. 57 (1992) Y1 - 1992 SN - 0033-8230 SP - 77 EP - 84 ER - TY - JOUR A1 - Scherer, Ulrich W. A1 - Brüchle, W. A1 - Schädel, M. A1 - Kratz, J. V. T1 - The Hydration Enthalpies of Md3+ and Lr3+ / W. Brüchle, M. Schädel, U.W. Scherer, J.V. Kratz, K.E. Gregorich, D. Lee, M. Nurmia, R.M. Chasteler, H.L. Hall, R.A. Henderson, D.C. Hoffman JF - Inorganica Chimica Acta. 146 (1988), H. 2 Y1 - 1988 SN - 0020-1693 SP - 267 EP - 276 ER - TY - JOUR A1 - Scherer, Ulrich W. A1 - Brüchle, W. A1 - Brügger, M. A1 - Frink, C. T1 - Reactions of 40Ar with 233U,,235U, and 238U at the Barrier / U.W. Scherer, W. Brüchle, M. Brügger, C. Frink, H. Gäggeler, G. Herrmann, J.V. Kratz, K.J. Moody, M. Schädel, K. Sümmerer, N. Trautmann, G. Wirth JF - Zeitschrift für Physik A Hadrons and Nuclei. 335 (1990), H. 4 Y1 - 1990 SN - 0939-7922 SP - 421 EP - 430 ER - TY - JOUR A1 - Scherer, Ulrich W. A1 - Baltensperger, Urs A1 - Ammann, Markus A1 - Bochert, Ulrich K. T1 - Use of 13N for Studies of the Selective Reduction of NO by NH3 over Vanadia/Titania Catalyst at Very Low Reactant Concentrations / Urs Baltensperger, Markus Ammann, Ulrich K. Bochert, Bernd Eichler, Heinz W. Gäggeler, Dieter T. Jost, Joseph A. Kovacs, An JF - Journal of Physical Chemistry. 97 (1993) Y1 - 1993 SN - 0022-3654 SP - 12325 EP - 12330 ER - TY - BOOK A1 - Scherer, Ulrich W. T1 - Untersuchungen zur Synthese und chemischen Charakterisierung sehr schwerer Elemente / Ulrich W. Scherer Y1 - 1989 N1 - zugl. Mainz, Univ., Diss. 1989. GSI-Bericht ; 89-18 PB - Gesellschaft für Schwerionenforschung mbH CY - Darmstadt ER - TY - BOOK A1 - Scherer, Ulrich W. T1 - Ultraschnelle Analytik radioaktiver Wirkstoffe : Abschlußbericht zu Nr. 3.2 und Anlage 2 BNBest-BMBF 98 ; Laufzeit des Vorhabens: 1.9.1999 -28.2.2001 / Zuwendungsempfänger: Ulrich W. Scherer Y1 - 2001 N1 - auch als gedruckte Ausgabe veröffentlicht PB - Universitätsbibliothek u. Technische Informationsbibliothek CY - Hannover ER - TY - JOUR A1 - Scherer, Ulrich W. T1 - Zur Radiopharmazie kardialer und kardiovaskulärer Radiopharmazeutika JF - Kardiologische Nuklearmedizin / G. Hör [Hrsg.] Y1 - 1997 SN - 3-609-62970-3 SP - 27 EP - 42 PB - ecomed CY - Landsberg ER - TY - JOUR A1 - Scherer, Ulrich W. T1 - Controlled ion track etching / J. George; M. Irkens ; S. Neumann ; U. W. Scherer ; A. Srivastava ; D. Sinha ; D. Fink JF - Radiation Effects and Defects in Solids. 161 (2006), H. 3 Y1 - 2006 SP - 161 EP - 175 ER - TY - JOUR A1 - Scheer, Nico A1 - Wolf, C. Roland T1 - Genetically humanized mouse models of drug metabolizing enzymes and transporters and their applications JF - Xenobiotica N2 - 1. Drug metabolizing enzymes and transporters play important roles in the absorption, metabolism, tissue distribution and excretion of various compounds and their metabolites and thus can significantly affect their efficacy and safety. Furthermore, they can be involved in drug–drug interactions which can result in adverse responses, life-threatening toxicity or impaired efficacy. Significant species differences in the interaction of compounds with drug metabolizing enzymes and transporters have been described. 2. In order to overcome the limitation of animal models in accurately predicting human responses, a large variety of mouse models humanized for drug metabolizing enzymes and to a lesser extent drug transporters have been created. 3. This review summarizes the literature describing these mouse models and their key applications in studying the role of drug metabolizing enzymes and transporters in drug bioavailability, tissue distribution, clearance and drug–drug interactions as well as in human metabolite testing and risk assessment. 4. Though such humanized mouse models have certain limitations, there is great potential for their use in basic research and for testing and development of new medicines. These limitations and future potentials will be discussed. KW - transporters KW - human metabolites KW - drug metabolising enzymes KW - drug–drug interactions KW - bioavailability Y1 - 2014 U6 - http://dx.doi.org/10.3109/00498254.2013.815831 SN - 1366-5928 VL - 44 IS - 2 SP - 96 EP - 108 PB - Taylor & Francis CY - Abingdon ER - TY - JOUR A1 - Scheer, Nico A1 - Wolf, C. Roland T1 - Xenobiotic receptor humanized mice and their utility JF - Drug Metabolism Reviews Y1 - 2013 U6 - http://dx.doi.org/10.3109/03602532.2012.738687 SN - 1097-9883 IS - 1 SP - 110 EP - 121 PB - Taylor & Francis CY - London ER - TY - JOUR A1 - Scheer, Nico A1 - Wilson, Ian D. T1 - A comparison between genetically humanized and chimeric liver humanized mouse models for studies in drug metabolism and toxicity JF - Drug Discovery Today N2 - Mice that have been genetically humanized for proteins involved in drug metabolism and toxicity and mice engrafted with human hepatocytes are emerging and promising in vivo models for an improved prediction of the pharmacokinetic, drug–drug interaction and safety characteristics of compounds in humans. The specific advantages and disadvantages of these models should be carefully considered when using them for studies in drug discovery and development. Here, an overview on the corresponding genetically humanized and chimeric liver humanized mouse models described to date is provided and illustrated with examples of their utility in drug metabolism and toxicity studies. We compare the strength and weaknesses of the two different approaches, give guidance for the selection of the appropriate model for various applications and discuss future trends and perspectives. Y1 - 2016 U6 - http://dx.doi.org/10.1016/j.drudis.2015.09.002 SN - 1359-6446 VL - 21 IS - 2 SP - 250 EP - 263 PB - Elsevier CY - Amsterdam ER - TY - JOUR A1 - Scheer, Nico A1 - Snaith, Mike A1 - Wolf, C. Roland A1 - Seibler, Jost T1 - Generation and utility of genetically humanized mouse models JF - Drug Discovery Today Y1 - 2013 U6 - http://dx.doi.org/10.1016/j.drudis.2013.07.007 SN - 1359-6446 VL - Vol 18 IS - 23-24 SP - 1200 EP - 1211 PB - Elsevier CY - Amsterdam ER - TY - JOUR A1 - Scheer, Nico A1 - Ross, Jillian A1 - Rode, Anja A1 - Zevnik, Branko A1 - Niehaves, Sandra A1 - Faust, Nicole A1 - Wolf, C. Roland T1 - A novel panel of mouse models to evaluate the role of human pregnane X receptor and constitutive androstane receptor in drug response JF - Journal of Clinical Investigation Y1 - 2008 U6 - http://dx.doi.org/https://doi.org/10.1172/JCI35483 SN - 1558-8238 VL - 118 IS - 9 SP - 3228 EP - 3239 ER - TY - JOUR A1 - Scheer, Nico A1 - Ross, Jillian A1 - Kapelyukh, Yury A1 - Rode, Anja A1 - Wolf, C. Roland T1 - In vivo responses of the human and murine pregnane X receptor to dexamethasone in mice JF - Drug Metabolism and Disposition N2 - Dexamethasone (DEX) is a potent and widely used anti-inflammatory and immunosuppressant glucocorticoid. It can bind and activate the pregnane X receptor (PXR), which plays a critical role as xenobiotic sensor in mammals to induce the expression of many enzymes, including cytochromes P450 in the CYP3A family. This induction results in its own metabolism. We have used a series of transgenic mouse lines, including a novel, improved humanized PXR line, to compare the induction profile of PXR-regulated drug-metabolizing enzymes after DEX administration, as well as looking at hepatic responses to rifampicin (RIF). The new humanized PXR model has uncovered further intriguing differences between the human and mouse receptors in that RIF only induced Cyp2b10 in the new humanized model. DEX was found to be a much more potent inducer of Cyp3a proteins in wild-type mice than in mice humanized for PXR. To assess whether PXR is involved in the detoxification of DEX in the liver, we analyzed the consequences of high doses of the glucocorticoid on hepatotoxicity on different PXR genetic backgrounds. We also studied these effects in an additional mouse model in which functional mouse Cyp3a genes have been deleted. These strains exhibited different sensitivities to DEX, indicating a protective role of the PXR and CYP3A proteins against the hepatotoxicity of this compound. Y1 - 2010 U6 - http://dx.doi.org/10.1124/dmd.109.031872 SN - 1521-009X VL - 38 IS - 7 SP - 1046 EP - 1053 PB - ASPET CY - Bethesda ER -